Antibody Drug Conjugates: Lessons From 20 Years of Clinical Experience

Ann Oncol. 2016 Dec;27(12):2168-2172. doi: 10.1093/annonc/mdw424. Epub 2016 Oct 11.

Abstract

Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.

Keywords: ADC; antibody drug conjugate.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / chemistry
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Drug Delivery Systems
  • Humans
  • Immunoconjugates / therapeutic use*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Pharmaceutical Preparations

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Immunoconjugates
  • Pharmaceutical Preparations